Minerva Neurosciences NERV
NASDAQ NERV
$2.53 +0.21 (+9.05%)
At close: Oct 20, 2026 · 4:00 PM EDT

Minerva Neurosciences (NERV) Short term Debt (2014)

Updated

Minerva Neurosciences (NERV) recorded Short term Debt of $1.38 million in Q2 2014.

Analysis

Minerva Neurosciences (NERV) Short term Debt (2014) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,146.94 Bn 1,115.53 Bn 19.71 Bn
2 Johnson & Johnson 624.96 Bn 543.49 Bn 17.26 Bn
3 AbbVie 510.15 Bn 483.27 Bn 12.70 Bn
4 Merck 366.13 Bn 320.51 Bn 12.21 Bn
5 Novartis Ag 297.75 Bn 261.74 Bn 11.24 Bn
6 Astrazeneca 261.93 Bn 235.62 Bn 12.86 Bn
7 Amgen 236.51 Bn 191.91 Bn 7.24 Bn
8 Gilead Sciences 194.27 Bn 168.47 Bn 6.22 Bn
9 Pfizer 171.74 Bn 118.39 Bn 10.94 Bn
10 Minerva Neurosciences 117.90 Mn -130.03 Mn -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2014 1.38 Mn
API Access

Minerva Neurosciences Short term Debt API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=short-term-debt&ticker=NERV&period=max&api_key=YOUR_API_KEY